Combining TMEM Doorway Score and Mena
MenaCalc
RMST difference
TMEM doorway
combined marker
metastasis
prognostic
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Apr 2022
26 Apr 2022
Historique:
received:
07
02
2022
revised:
18
04
2022
accepted:
25
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
to develop several digital pathology-based machine vision algorithms for combining TMEM and Mena This retrospective study included a subset of 130 patients (65 patients with no recurrence and 65 patients with a recurrence at 5 years) from the Calgary Tamoxifen cohort of breast cancer patients. Patients had confirmed invasive breast cancer and received adjuvant tamoxifen therapy. Of the 130 patients, 86 cases were suitable for analysis in this study. Sequential sections of formalin-fixed paraffin-embedded patient samples were stained for TMEM doorways (immunohistochemistry triple staining) and Mena the best performing combined marker gave an RMST difference of 5.27 years (95% CI: 1.71-8.37), compared to 3.56 years (95% CI: 0.95-6.1) for the associated standalone TMEM doorway analysis and 2.94 years (95% CI: 0.25-5.87) for the associated standalone Mena combining TMEM doorway and Mena
Identifiants
pubmed: 35565297
pii: cancers14092168
doi: 10.3390/cancers14092168
pmc: PMC9101795
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : CA240646
Pays : United States
Organisme : NIH HHS
ID : OD019961
Pays : United States
Organisme : NCI NIH HHS
ID : CA013330
Pays : United States
Organisme : NIH HHS
ID : CA216248
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002556
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Breast Cancer Res. 2015 May 03;17:65
pubmed: 25935535
Circulation. 2019 Oct 22;140(17):1366-1368
pubmed: 31634007
Ann Intern Med. 2015 Jul 21;163(2):127-34
pubmed: 26054047
NPJ Breast Cancer. 2017 Nov 8;3:42
pubmed: 29138761
N Engl J Med. 2021 Dec 16;385(25):2336-2347
pubmed: 34914339
Mod Pathol. 2016 Aug;29(8):799-809
pubmed: 27125355
J Natl Cancer Inst. 2014 Jun 03;106(8):
pubmed: 24895374
Dev Cell. 2008 Dec;15(6):813-28
pubmed: 19081071
Breast Cancer Res. 2012 Sep 12;14(5):R124
pubmed: 22971274
Cancers (Basel). 2020 Mar 31;12(4):
pubmed: 32244564
Surg Oncol Clin N Am. 2010 Jul;19(3):581-606
pubmed: 20620929
J Clin Oncol. 2014 Aug 1;32(22):2380-5
pubmed: 24982461
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Trends Cell Biol. 2011 Feb;21(2):81-90
pubmed: 21071226
Clin Cancer Res. 2013 Dec 1;19(23):6389-97
pubmed: 24298069
Sci Transl Med. 2017 Jul 5;9(397):
pubmed: 28679654
Control Clin Trials. 1997 Apr;18(2):151-67
pubmed: 9129859
Clin Exp Metastasis. 2011 Aug;28(6):515-27
pubmed: 21484349
J Cell Sci. 2011 Jul 1;124(Pt 13):2120-31
pubmed: 21670198
J Clin Oncol. 2011 Nov 10;29(32):4273-8
pubmed: 21990413
BMC Med Res Methodol. 2013 Dec 07;13:152
pubmed: 24314264
Cancer Res. 2007 Mar 15;67(6):2649-56
pubmed: 17363585
J Hyg (Lond). 1949 Jun;47(2):188
pubmed: 15406758
Clin Cancer Res. 2009 Apr 1;15(7):2433-41
pubmed: 19318480
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Cancer Discov. 2015 Sep;5(9):932-43
pubmed: 26269515
Nat Rev Cancer. 2005 Aug;5(8):591-602
pubmed: 16056258
Nat Rev Cancer. 2011 Jul 22;11(8):573-87
pubmed: 21779009
JAMA Cardiol. 2017 Nov 1;2(11):1179-1180
pubmed: 28877311
BMC Cancer. 2015 Jun 27;15:483
pubmed: 26112005
Otolaryngol Head Neck Surg. 2010 Sep;143(3):331-6
pubmed: 20723767
Cold Spring Harb Protoc. 2011 Oct 01;2011(10):1232-4
pubmed: 21969630
Immunotherapy. 2021 Feb;13(2):95-101
pubmed: 33148090
Cancer Res. 2004 Oct 1;64(19):7022-9
pubmed: 15466195
Cancer Res. 2000 Oct 1;60(19):5401-4
pubmed: 11034079
Oncogene. 2017 May 11;36(19):2680-2692
pubmed: 27893712
Trends Cell Biol. 2017 Aug;27(8):595-607
pubmed: 28412099